Stock IRLAB A IRLAB THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:43 2024-05-31 am EDT 		5-day change 1st Jan Change
15.6 SEK -0.95% Intraday chart for IRLAB Therapeutics AB -0.95% +108.00%
May. 27 Sweden’s IRLAB Therapeutics Names New CEO MT
May. 27 IRLAB Therapeutics AB Announces CEO Changes, Effective from August 1, 2024 CI

Strengths

  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
IRLAB THERAPEUTICS AB Stock IRLAB Therapeutics AB
+108.00% 76.81M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
A+
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
C+
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IRLAB A Stock
  4. Ratings IRLAB Therapeutics AB